Diurnal IOP Control with Bimatoprost Versus Latanoprost in Exfoliative Glaucoma: a Crossover, Observer-masked, Three-centre Study

Overview

Journal Br J Ophthalmol

Specialty Ophthalmology

Date 2006 Nov 25

PMID 17124241

Citations 18

Authors

A G P Konstas

G Hollo

M Irkec

S Tsironi

I Durukan

M Goldenfeld

S Melamed

Affiliations

Soon will be listed here.

Abstract

Aim: To evaluate the diurnal intraocular pressure (IOP) control and safety of bimatoprost versus latanoprost in exfoliative glaucoma (XFG).

Methods: One eye of 129 consecutive patients with XFG (mean (SD) age 66.5 (8.3) years) was included in this prospective, observer-masked, three-centre, crossover comparison. After a 4-6 week medicine-free period patients were randomised to bimatoprost or latanoprost monotherapy for 3 months. Patients were then switched to the opposite treatment for another 3 months. At the end of the washout and the treatment periods diurnal IOP was measured at 0800, 1300, and 1800.

Results: At baseline the IOP (mean (SD)) was 28.0 (4.0), 26.9 (3.6), and 25.9 (3.6) mm Hg, at the three time points, respectively. Both treatments significantly reduced mean diurnal IOP at month 3. Mean diurnal IOP was 26.9 (3.5) mm Hg at baseline, 17.6 (3.3) mm Hg with bimatoprost, and 18.6 (3.6) mm Hg with latanoprost (p<0.0001). Furthermore, lower IOP values were obtained with bimatoprost at all time points (17.9 (3.4), 17.3 (3.3), and 17.6 (3.5) mm Hg, respectively) compared with latanoprost (18.7 (3.6), 18.5 (3.6), and 18.6 (4.1) mm Hg, respectively). The corresponding mean differences (0.8, 1.1, and 1.0 mm Hg, respectively) were all significant (p<0.001 for each comparison). Significantly more patients with XFG obtained a target diurnal IOP <17 mm Hg with bimatoprost than with latanoprost, 55/123 (45%) v 34/123 (28%); (p = 0.001), and significantly fewer patients were non-responders with bimatoprost than with latanoprost (5 v 13, p = 0.021). More patients reported at least one adverse event with bimatoprost than with latanoprost (58 v 41 at 3 months; p = 0.0003).

Conclusion: This crossover study suggests that better diurnal IOP control is obtained with bimatoprost than with latanoprost in patients with XFG.

Citing Articles

Pseudoexfoliation Syndrome-Clinical Characteristics of Most Common Cause of Secondary Glaucoma.

Tomczyk-Socha M, Tomczak W, Winkler-Lach W, Turno-Krecicka A J Clin Med. 2023; 12(10).

PMID: 37240686 PMC: 10218815. DOI: 10.3390/jcm12103580.

Fibrotic Response of Human Trabecular Meshwork Cells to Transforming Growth Factor-Beta 3 and Autotaxin in Aqueous Humor.

Liu M, Honjo M, Yamagishi R, Igarashi N, Nakamura N, Kurano M Biomolecules. 2022; 12(9).

PMID: 36139071 PMC: 9496180. DOI: 10.3390/biom12091231.

Retrospective Analysis of Switching Bimatoprost 0.01% to Bimatoprost 0.03% in Patients with Various Types of Glaucoma and Ocular Hypertension.

Xu K, Cho R, Chan T Clin Ophthalmol. 2022; 16:2385-2390.

PMID: 35936971 PMC: 9346412. DOI: 10.2147/OPTH.S368214.

[Secondary open-angle glaucoma: pseudoexfoliative glaucoma, pigmentary glaucoma and neovascular glaucoma].

Greslechner R, Helbig H, Spiegel D Ophthalmologe. 2022; 119(4):425-438.

PMID: 35362756 DOI: 10.1007/s00347-022-01609-3.

Analysis of the Responsiveness of Latanoprost, Travoprost, Bimatoprost, and Tafluprost in the Treatment of OAG/OHT Patients.

Cai Z, Cao M, Liu K, Duan X J Ophthalmol. 2021; 2021:5586719.

PMID: 34123413 PMC: 8169256. DOI: 10.1155/2021/5586719.

References

Konstas A, Maltezos A, Bufidis T, Hudgins A, Stewart W . Twenty-four hour control of intraocular pressure with dorzolamide and timolol maleate in exfoliation and primary open-angle glaucoma. Eye (Lond). 2001; 14 ( Pt 1):73-7. DOI: 10.1038/eye.2000.16. View

Konstas A, Kozobolis V, Katsimpris I, Boboridis K, Koukoula S, Jenkins J . Efficacy and safety of latanoprost versus travoprost in exfoliative glaucoma patients. Ophthalmology. 2007; 114(4):653-7. DOI: 10.1016/j.ophtha.2006.07.064. View

DuBiner H, Cooke D, Dirks M, Stewart W, VanDenburgh A, Felix C . Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost. Surv Ophthalmol. 2001; 45 Suppl 4:S353-60. DOI: 10.1016/s0039-6257(01)00212-0. View

Gandolfi S, SIMMONS S, Sturm R, Chen K, VanDenburgh A . Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther. 2001; 18(3):110-21. DOI: 10.1007/BF02850299. View

Easthope S, Perry C . Topical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension. Drugs Aging. 2002; 19(3):231-48. DOI: 10.2165/00002512-200219030-00008. View

Heijl A, Leske M, Bengtsson B, Hyman L, Bengtsson B, Hussein M . Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002; 120(10):1268-79. DOI: 10.1001/archopht.120.10.1268. View

Noecker R, Dirks M, Choplin N, Bernstein P, Batoosingh A, Whitcup S . A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol. 2002; 135(1):55-63. DOI: 10.1016/s0002-9394(02)01827-5. View

Konstas A, Kozobolis V, Tersis I, Leech J, Stewart W . The efficacy and safety of the timolol/dorzolamide fixed combination vs latanoprost in exfoliation glaucoma. Eye (Lond). 2003; 17(1):41-6. DOI: 10.1038/sj.eye.6700257. View

Parrish R, Palmberg P, Sheu W . A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol. 2003; 135(5):688-703. DOI: 10.1016/s0002-9394(03)00098-9. View

10.

Ritch R, Schlotzer-Schrehardt U, Konstas A . Why is glaucoma associated with exfoliation syndrome?. Prog Retin Eye Res. 2003; 22(3):253-75. DOI: 10.1016/s1350-9462(02)00014-9. View

11.

Coleman A, Lerner F, Bernstein P, Whitcup S . A 3-month randomized controlled trial of bimatoprost (LUMIGAN) versus combined timolol and dorzolamide (Cosopt) in patients with glaucoma or ocular hypertension. Ophthalmology. 2003; 110(12):2362-8. DOI: 10.1016/s0161-6420(03)00662-6. View

12.

Konstas A, Hollo G, Astakhov Y, Teus M, Akopov E, Jenkins J . Factors associated with long-term progression or stability in exfoliation glaucoma. Arch Ophthalmol. 2004; 122(1):29-33. DOI: 10.1001/archopht.122.1.29. View

13.

Konstas A, Mylopoulos N, Karabatsas C, Kozobolis V, Diafas S, Papapanos P . Diurnal intraocular pressure reduction with latanoprost 0.005% compared to timolol maleate 0.5% as monotherapy in subjects with exfoliation glaucoma. Eye (Lond). 2004; 18(9):893-9. DOI: 10.1038/sj.eye.6701345. View

14.

Heijl A, Strahlman E, Sverrisson T, Puustjarvi T, Tipping R . A comparison of dorzolamide and timolol in patients with pseudoexfoliation and glaucoma or ocular hypertension. Ophthalmology. 1997; 104(1):137-42. DOI: 10.1016/s0161-6420(97)30348-0. View

15.

Konstas A, Mantziris D, Stewart W . Diurnal intraocular pressure in untreated exfoliation and primary open-angle glaucoma. Arch Ophthalmol. 1997; 115(2):182-5. DOI: 10.1001/archopht.1997.01100150184006. View

16.

Konstas A, Stewart W, Stroman G, Sine C . Clinical presentation and initial treatment patterns in patients with exfoliation glaucoma versus primary open-angle glaucoma. Ophthalmic Surg Lasers. 1997; 28(2):111-7. View

17.

Konstas A, Mantziris D, Cate E, Stewart W . Effect of timolol on the diurnal intraocular pressure in exfoliation and primary open-angle glaucoma. Arch Ophthalmol. 1997; 115(8):975-9. DOI: 10.1001/archopht.1997.01100160145002. View

18.

Konstas A, Katsimbris J, Lallos N, Boukaras G, Jenkins J, Stewart W . Latanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patients. Ophthalmology. 2005; 112(2):262-6. DOI: 10.1016/j.ophtha.2004.08.022. View

19.

Law S, Song B, Fang E, Caprioli J . Feasibility and efficacy of a mass switch from latanoprost to bimatoprost in glaucoma patients in a prepaid Health Maintenance Organization. Ophthalmology. 2005; 112(12):2123-30. DOI: 10.1016/j.ophtha.2005.06.031. View

20.

Konstas A, Tsironi S, Ritch R . Current concepts in the pathogenesis and management of exfoliation syndrome and exfoliative glaucoma. Compr Ophthalmol Update. 2006; 7(3):131-41. View